Drug intelligence / Profile preview

Lu AF09535

Development stage: Unknown
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Oral

Overview

Lu AF09535 is an investigational small molecule new chemical entity (NCE) developed by Lundbeck for the treatment of mood disorders. In a Phase I first-in-man clinical trial, the compound demonstrated unexpectedly low systemic exposure in humans. Subsequent investigations using 14C-microdose accelerator mass spectrometry (AMS) revealed that this was caused by extensive metabolism through a human-specific pathway not present in preclinical species. The specific molecular target and chemical structure of Lu AF09535 remain proprietary and have not been publicly disclosed.

Beyond the preview

Go deeper on Lu AF09535.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu AF09535.

Explore the full profile